Top Markets
#1 Siren Siren +43.80%
#2 Seeker Seeker +24.90%
#3 Full Moon Full Moon +19.61%
#4 Wrapped NXM Wrapped NXM +12.15%
#5 Zora Zora +10.73%
#6 FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock) +10.64%
#7 VVS Finance VVS Finance +9.99%
#8 Cryptopia Cryptopia +9.26%
#9 Axelar Axelar +8.27%
#10 Helium Helium +8.16%
Coin of the day
Siren Siren
Setări
Limbă
ROMâNă
Monedă
USD
Temă
Silence Therapeutics plc Silence Therapeutics plc

Silence Therapeutics plc

SLN
Rang în acțiuni #12014
Silence Therapeutics plc is a London, UK-based biotechnology company... Silence Therapeutics plc is a London, UK-based biotechnology company specializing in the research and development of groundbreaking ribonucleic acid (RNA) therapeutics. Its therapeutic focus areas include hematological, cardiovascular, and various rare and metabolic conditions. Central to their innovative approach is the mRNAi GalNAc Oligonucleotide Discovery platform, which is designed for precise targeting of specific disease-causing genes within the liver. The company's methodology harnesses the body's natural RNA interference (RNAi) mechanism by designing short interfering RNA (siRNA) molecules that degrade messenger RNA (mRNA), thereby preventing the production of targeted disease-associated proteins. Their pipeline features several promising candidates, including SLN360, currently in Phase I clinical trials for cardiovascular disease associated with elevated lipoprotein. Another key candidate, SLN124, is undergoing Phase I clinical trials for non-transfusion-dependent thalassemia and myelodysplastic syndrome, with further development planned for polycythemia vera. Silence Therapeutics also engages in strategic collaborations to expand its reach. It has agreements with AstraZeneca PLC to discover, develop, and commercialize siRNA therapeutics for cardiovascular, renal, metabolic, and respiratory diseases. Furthermore, a partnership with Mallinckrodt Pharma IP Trading DAC aims to develop and commercialize RNAi drug targets designed to silence the complement cascade in complement-mediated disorders. The company is also collaborating with Hansoh Pharmaceutical Group Company Limited to develop siRNAs for three unspecified targets, utilizing Silence's mRNAi GOLD platform. Originally incorporated as SR Pharma plc, the company rebranded to Silence Therapeutics plc in May 2007.
Preț acțiune
$13.34
Ultima sincronizare: 2026-08-28
Capitalizare de piață
$629.93M
Schimbare (1 zi)
-0.84%
Schimbare (1 an)
177.26%
Țară
GB
Tranzacționează Silence Therapeutics plc (SLN)

Categorie

Healthcare
Istoric al prețului acțiunii pentru Silence Therapeutics plc (SLN)
Cel mai mare preț de închidere: $13.70 pe 2026-08-01

Cel mai mic preț de închidere: $18.26 pe 2020-09-01
Istoric al prețului acțiunii pentru Silence Therapeutics plc din 2020 până în 2026
Evoluția anuală a prețului acțiunii
An Performanță
2026 (TTM) 10.68%
2025 -10.61%
2024 -54.38%
2023 3.22%
2022 -37.25%
2021 25.25%
2020 0.00%
Prețul acțiunii pentru companii similare sau concurente
Companie Preț acțiune Variație 1an% Țara
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $542.09 38.63%
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $1.03K 44.13%
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
 $121.36 -12.82%
AU
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 $138.18 473.58%
US
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 $759.27 7.20%
CH